The oral contraceptive, drospirenone/17b-estradiol, can significantly boost enalapril’s blood pressure-lowering effect in postmenopausal women with hypertension.
Aldosterone has been implicated in the pathogenesis of progressive cardiovascular disease. Drospirenone is a novel progestin with aldosterone receptor antagonist activity.
Richard A. Preston, at the University of Miami School of Medicine, in Miami, Florida, United States, and colleagues compared the additive effect of drospirenone/17b-estradiol versus placebo on 24-hour ambulatory blood pressure in postmenopausal women with hypertension treated with enalapril maleate.
In this double-blind, two-parallel group trial, 24 postmenopausal women, who were receiving 10 mg of enalapril twice a day prior to the study, were randomized to receive drospirenone/17b-estradiol plus enalapril or placebo plus enalapril for 14 days. Twenty-four-hour ambulatory blood pressure, plasma renin activity, and serum aldosterone were determined at baseline and on day 14.
e-Med Tools
קצר קולע וממוקד
e-Med סמינרים
אי-מד תחקירים
Medscape Tools
Journal Club
מרכזי מידע ושירות
Facebook
מידע למפרסם
מאגר תרופות
מאגר אנשי המקצוע
אינדקס שימושי
חדשות משה"ב
eMed HealthClub
מחקרים קליניים
השאירו תגובה
רוצה להצטרף לדיון?תרגישו חופשי לתרום!